{
    "eid": "2-s2.0-85097018464",
    "title": "Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials",
    "cover-date": "2021-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anticoagulants",
        "pancreatic neoplasms",
        "thromboembolism",
        "thrombosis",
        "venous thromboembolism"
    ],
    "authors": [
        "Thita Chiasakul",
        "Rushad Patell",
        "Anthony Maraveyas",
        "Marc Carrier",
        "Jeffrey I. Zwicker"
    ],
    "citedby-count": 11,
    "ref-count": 46,
    "ref-list": [
        "Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer",
        "Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States",
        "Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer",
        "Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes",
        "Primary thromboprophylaxis in pancreatic cancer patients. Why clinical practice guidelines should be implemented",
        "Cancer and venous thromboembolic disease: a review",
        "Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis",
        "Apixaban to prevent venous thromboembolism in patients with cancer",
        "Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer",
        "Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer",
        "Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial",
        "Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297",
        "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer",
        "Randomized phase iii multi-institutional study of tnferade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results",
        "Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer",
        "Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study",
        "Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)",
        "Low molecular heparin in prevention of thromboembolism in out-patients with non-resectable pancreatic cancer",
        "Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE",
        "Matrix metalloproteinases: target for new cancer therapies",
        "A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine",
        "A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer",
        "PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy",
        "BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer",
        "Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies",
        "Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study",
        "Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)",
        "Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate",
        "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial",
        "Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer",
        "Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer",
        "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine",
        "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial",
        "MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)",
        "Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial",
        "National Cancer Institute of Canada Clinical Trials G. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group",
        "Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?",
        "Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project",
        "Adverse event reporting in oncology clinical trials - lost in translation?",
        "Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings",
        "international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer",
        "Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update",
        "The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH",
        "Prevention of venous thromboembolism in pancreatic cancer: breaking down a complex clinical dilemma",
        "Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hull",
            "@id": "60107756",
            "affilname": "Hull York Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60107756",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Ottawa",
            "@id": "60002173",
            "affilname": "Ottawa Hospital Research Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002173",
            "affiliation-country": "Canada"
        }
    ],
    "funding": [
        "BMS",
        "Pfizer",
        "Bayer",
        "Leo Pharma"
    ]
}